Financial Performance - HBC recorded total operating revenues of NOK 72.2 million in Q4 2025, an increase from NOK 64.9 million in Q4 2024. Full year 2025 total operating revenues amounted to NOK 256.3 million compared to NOK 265.5 million in 2024 [1] - EBITDA for Q4 2025 was negative NOK 26.5 million, slightly worse than negative NOK 26.1 million in Q4 2024. For the full year 2025, EBITDA was negative NOK 72.9 million compared to negative NOK 65.3 million in 2024 [2] - Cash and cash equivalents increased by NOK 1.6 million during Q4 2025, ending at NOK 67.1 million as of December 31, 2025, with total liquidity reaching NOK 77.5 million [3] Product and Market Development - Human Nutrition B2B revenues increased by 300% year-on-year, driven by strong demand for ProGo® and CalGo®, along with a solid sales start for NT-II™ [6] - Expanded regulatory access achieved with ingredient approvals in Australia and South Korea, facilitating entry into large VMS and functional food markets [6] - Pet Nutrition B2B volumes and revenues improved, supported by increased customer engagement and trade-show activity [6] Research and Development - Significant R&D milestones achieved during Q4, including peer-review publication of the CalGo® bone health study and IRB approval for a clinical NT-II™ joint health study [6] - HBC has identified unique health benefits through scientific evidence, leading to important academic partnerships and the granting of several patents [5] Corporate Actions - HBC raised NOK 158 million in a private placement and sold a stake in AecorBio Inc. for USD 5 million during Q4, with transactions expected to finalize in Q1 2026 to support growth and R&D [6] - HBC spun out a biotech-focused company, HBC Immunology (HBCI), which has raised external finance for its lead program in prostate cancer [7]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - A class action lawsuit has been initiated against uniQure N.V. for alleged securities fraud, with a focus on misrepresentations regarding the company's drug candidate and regulatory approvals [1] Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1] - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [1] Group 2: Legal Representation - Rosen Law Firm, known for its success in securities class actions, is leading the lawsuit and encourages investors to select qualified counsel [1] - The firm has a strong track record, having achieved significant settlements for investors, including over $438 million in 2019 [1] - Investors can join the class action by contacting Rosen Law Firm through their website or phone [1] Group 3: Implications for Investors - The lawsuit alleges that when the true details about uniQure's business and operations were revealed, investors suffered damages [1] - A lead plaintiff is needed to represent the class, and interested parties must move the Court by April 13, 2026 [1] - Until the class is certified, investors are not represented by counsel unless they retain one [1]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for securities law violations, specifically for making false and misleading statements regarding its FDA approval process and study design [1] Group 1: Lawsuit Details - The lawsuit pertains to violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from September 24, 2025, to October 31, 2025, with a deadline for lead plaintiff appointments set for April 13, 2026 [1] - The complaint alleges that uniQure's public statements were materially misleading, particularly regarding the likelihood of delays in its Biologics License Application (BLA) with the FDA due to the need for additional studies [1] Group 2: Company Background - uniQure N.V. is a biotechnology company that focuses on gene therapies [1] - The company is listed on NASDAQ under the ticker symbol QURE [1] - The DJS Law Group, which is handling the lawsuit, specializes in securities class actions and corporate governance litigation [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. for the period between September 24, 2025, and October 31, 2025, due to alleged misrepresentations regarding the company's drug candidate and its regulatory approval status [1]. Group 1: Lawsuit Details - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline, which led to investors suffering damages when the true information became public [5]. - Investors who purchased uniQure shares during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information. A lead plaintiff must file a motion by April 13, 2026 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].

Good afternoon, and welcome to the HotCopper HotList column. Every week, ASX companies of every shape and size go through the ups and downs that is the Australian trading rollercoaster. Fortunes made, and equity lost each time the bourse opens – which is why watching market trends is so key.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.You certainily don’t have to go it alone, though: We’ve put togethe ...

【siRNA行业观点：递送平台有望迎来突破，关注减重、CNS及双靶方向】 # siRNA药物具备高效低毒、疗效持久的优势 相较于传统小分和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已成 为新药开发热门方向，BD交易频出，根据弗若斯特沙利数据全球siRNA药物市场有望在2040年达到503亿美元。 # GalNAc肝内递送平台已较为成熟，肝外递送 【siRNA行业观点：递送平台有望迎来突破，关注减重、CNS及双靶方向】 # siRNA药物具备高效低毒、疗效持久的优势 相较于传统小分和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已成 为新药开发热门方向，BD交易频出，根据弗若斯特沙利数据全球siRNA药物市场有望在2040年达到503亿美元。 # GalNAc肝内递送平台已较为成熟，肝外递送有望迎来突破 siRNA行业先驱Alnylam开发的GalNAc肝内递送凭借递送效率极高、特异性强以及作用持久等优势，已成为肝内靶 点siRNA药物的"标准答案"，如针对PCSK9、AGT、Lp(a)以及APoC3等心血管常见靶点的siRNA药物 ...

Core Viewpoint - Coherus Oncology, Inc. has announced a public offering of 28,600,000 shares of common stock at a price of $1.75 per share, aiming to raise approximately $50.1 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering price is set at $1.75 per share, with gross proceeds expected to be around $50.1 million before underwriting discounts and commissions [1]. - The company has granted underwriters a 30-day option to purchase an additional 4,290,000 shares at the public offering price [1]. - The offering is anticipated to close on or about February 17, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - Coherus plans to utilize the net proceeds from the offering to support the commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of its product candidates, and for working capital and other general corporate purposes [2]. Group 3: Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes mid-stage clinical candidates targeting various cancers [5]. - The company's strategy focuses on growing sales of LOQTORZI in R/M nasopharyngeal carcinoma and advancing new indications in combination with its pipeline candidates and partners [5]. Group 4: Pipeline Information - Coherus' pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses to improve cancer treatment outcomes [6]. - Tagmokitug, a selective anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors, while Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [6].

New York, New York--(Newsfile Corp. - February 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023, and December 26, 2025. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026.SO WHAT: If you purchased Mereo ADSs during the Class Period you may be e ...

Ultragenyx (RARE) reported $207 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 25.6%. EPS of -$1.29 for the same period compares to -$1.39 a year ago.The reported revenue represents a surprise of +2.01% over the Zacks Consensus Estimate of $202.92 million. With the consensus EPS estimate being -$1.20, the EPS surprise was -7.32%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...